Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients
Identifieur interne : 003845 ( Main/Exploration ); précédent : 003844; suivant : 003846Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients
Auteurs : Zhi Liu [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-06.
English descriptors
- KwdEn :
- Aged, Benzamides (chemistry), Benzamides (therapeutic use), Colon (drug effects), Constipation (drug therapy), Constipation (etiology), Female, Functional Laterality, Gastrointestinal Transit (drug effects), Humans, Male, Middle Aged, Morpholines (chemistry), Morpholines (therapeutic use), Parkinson Disease (complications), Parkinson's disease, Serotonin 5-HT3 Receptor Agonists, Serotonin 5-HT4 Receptor Agonists, Treatment Outcome, Video Recording (methods), constipation, mosapride citrate, multiple system atrophy, serotonin.
- MESH :
- chemical , chemistry : Benzamides, Morpholines.
- chemical , therapeutic use : Benzamides, Morpholines.
- complications : Parkinson Disease.
- drug effects : Colon, Gastrointestinal Transit.
- drug therapy : Constipation.
- etiology : Constipation.
- methods : Video Recording.
- Aged, Female, Functional Laterality, Humans, Male, Middle Aged, Serotonin 5-HT3 Receptor Agonists, Serotonin 5-HT4 Receptor Agonists, Treatment Outcome.
Abstract
Mosapride citrate is a novel selective 5‐HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K+ channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre‐ and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20387
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001467
- to stream Istex, to step Curation: 001467
- to stream Istex, to step Checkpoint: 002253
- to stream PubMed, to step Corpus: 003145
- to stream PubMed, to step Curation: 003145
- to stream PubMed, to step Checkpoint: 003058
- to stream Ncbi, to step Merge: 001156
- to stream Ncbi, to step Curation: 001156
- to stream Ncbi, to step Checkpoint: 001156
- to stream Main, to step Merge: 004F30
- to stream Main, to step Curation: 003845
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients</title><author><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name></author><author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name></author><author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name></author><author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name></author><author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name></author><author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1DD6BB45EDE0237ED5389D0452C0B0641CA124C3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20387</idno><idno type="url">https://api.istex.fr/document/1DD6BB45EDE0237ED5389D0452C0B0641CA124C3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001467</idno><idno type="wicri:Area/Istex/Curation">001467</idno><idno type="wicri:Area/Istex/Checkpoint">002253</idno><idno type="wicri:doubleKey">0885-3185:2005:Liu Z:mosapride:citrate:a</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15719424</idno><idno type="wicri:Area/PubMed/Corpus">003145</idno><idno type="wicri:Area/PubMed/Curation">003145</idno><idno type="wicri:Area/PubMed/Checkpoint">003058</idno><idno type="wicri:Area/Ncbi/Merge">001156</idno><idno type="wicri:Area/Ncbi/Curation">001156</idno><idno type="wicri:Area/Ncbi/Checkpoint">001156</idno><idno type="wicri:doubleKey">0885-3185:2005:Liu Z:mosapride:citrate:a</idno><idno type="wicri:Area/Main/Merge">004F30</idno><idno type="wicri:Area/Main/Curation">003845</idno><idno type="wicri:Area/Main/Exploration">003845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients</title><author><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of 1st Internal Medicine, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of 1st Internal Medicine, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of 1st Internal Medicine, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-06">2005-06</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="680">680</biblScope><biblScope unit="page" to="686">686</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1DD6BB45EDE0237ED5389D0452C0B0641CA124C3</idno><idno type="DOI">10.1002/mds.20387</idno><idno type="ArticleID">MDS20387</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Benzamides (chemistry)</term><term>Benzamides (therapeutic use)</term><term>Colon (drug effects)</term><term>Constipation (drug therapy)</term><term>Constipation (etiology)</term><term>Female</term><term>Functional Laterality</term><term>Gastrointestinal Transit (drug effects)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Morpholines (chemistry)</term><term>Morpholines (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson's disease</term><term>Serotonin 5-HT3 Receptor Agonists</term><term>Serotonin 5-HT4 Receptor Agonists</term><term>Treatment Outcome</term><term>Video Recording (methods)</term><term>constipation</term><term>mosapride citrate</term><term>multiple system atrophy</term><term>serotonin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Benzamides</term><term>Morpholines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzamides</term><term>Morpholines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Colon</term><term>Gastrointestinal Transit</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Video Recording</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Functional Laterality</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Serotonin 5-HT3 Receptor Agonists</term><term>Serotonin 5-HT4 Receptor Agonists</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mosapride citrate is a novel selective 5‐HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K+ channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre‐ and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name></noRegion><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1DD6BB45EDE0237ED5389D0452C0B0641CA124C3
|texte= Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients
}}
| This area was generated with Dilib version V0.6.23. |  |